HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on LifeMD (NASDAQ:LFMD) and maintained a $12 price target on the stock.

March 12, 2024 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD receives a reiterated Buy rating and a maintained $12 price target from HC Wainwright & Co. analyst Yi Chen.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest confidence in the company's future performance, potentially leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100